Aurobindo Pharma’s $900 Million Acquisition of Novartis’ Sandoz Generic Assets

Baker Botts advised Novartis on the sale

Novartis today has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US over the long-term.

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects. The sale includes the Sandoz US generic and branded dermatology businesses as well as its dermatology development center. As part of the transaction, Aurobindo will acquire the manufacturing facilities in Wilson, North Carolina, as well as Hicksville and Melville, New York. The business had net sales of USD 0.6 billion in H1, 2018.

As part of the agreement, approximately 750 employees in Hicksville, Melville, Wilson and Princeton, New Jersey, as well as the field representatives for the PharmaDerm branded dermatology business, are expected to transfer to Aurobindo upon closing.

Following the transaction, the Sandoz US portfolio will continue to be substantial, and will include biosimilars, value-added medicines and complex generics such as injectables, respiratory and ophthalmics. Sandoz will continue to focus its clinical development, business development and investment efforts on these areas.

The transaction is expected to close in the course of 2019 following the completion of customary closing conditions.

Baker Botts advised Novartis with a team including partners Steve Weissman (Picture) and Michael Perry, who are supported by associates Matt Adler and Tim Singer.

Involved fees earner: Stephen Weissman – Baker Botts; Michael Perry – Baker Botts; Matthew Adler – Baker Botts; Timothy Singer – Baker Botts;

Law Firms: Baker Botts;

Clients: Novartis;

Author: Ambrogio Visconti